细菌溶解产物胶囊分别联合氟替美维与布地格福治疗老年慢性阻塞性肺疾病急性加重期的疗效观察
Efficacy of Bacterial Lysate Capsules Combined with Futimeiwei or Budigefu in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Elderly Patients
张倩倩 1张艳艳 1聂丽 1钱会 1蒋亚林1
作者信息
- 1. 亳州市人民医院南院呼吸科,安徽 亳州 236800
- 折叠
摘要
目的:探讨细菌溶解产物胶囊分别联合氟替美维与布地格福治疗老年慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效.方法:选取 2022 年 10 月至 2023 年 5 月于该院门急诊入院的老年AECOPD患者 100 例,采用随机数字表法分为氟替美维组和布地格福组,各 50 例.两组患者根据指南接受AECOPD常规治疗,同时服用细菌溶解产物胶囊 10 d;氟替美维组患者接受氟替美维治疗,布地格福组患者接受布地格福治疗,两组患者出院时继续接受氟替美维或布地格福治疗.治疗 1 个月时进行效果评价,评价指标包括血气分析、肺功能、炎症因子和不良反应.结果:治疗后,两组患者动脉血氧分压(PaO2)、血氧饱和度(SaO2)相比治疗前升高,二氧化碳分压(PaCO2)相比治疗前降低,差异均有统计学意义(P<0.05);但两组患者治疗后的PaO2、PaCO2 和SaO2 比较,差异无统计学意义(P>0.05).治疗后,两组患者第 1 秒用力呼吸容积(FEV1)、用力肺活量(FVC)和FEV1/FVC水平相比治疗前升高,布地格福组患者的FEV1、FVC和FEV1/FVC水平高于氟替美维组,差异均有统计学意义(P<0.05).治疗后,两组患者血清C反应蛋白、白细胞介素 6 水平相比治疗前降低,布地格福组患者低于氟替美维组,差异均有统计学意义(P<0.05).两组患者肝肾功能异常、肺炎、头痛、皮疹和胃食管反流等不良反应发生率比较,差异无统计学意义(P>0.05).结论:细菌溶解产物胶囊联合氟替美维或布地格福治疗老年AECOPD患者,均能有效改善动脉血气,布地格福在改善肺功能和抗炎方面略有优势,且没有增加不良反应.
Abstract
OBJECTIVE:To probe into the clinical efficacy of Bacterial lysate capsules respectively combined Futimeiwei and Budigefu in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)in elderly patients.METHODS:A total of 100 elderly patients with AECOPD admitted to the outpatient emergency department from Oct.2022 to May 2023 were selected to be randomly divided into Futimeiwei group and Budigefu group via random number table method,with 50 cases in each group.Both groups received regular treatment for AECOPD according to the guidelines,while taking Bacterial lysate capsules for 10 d,the Futimeiwei group was given Futimeiwei and the Budigefu group was given Budigefu,both groups continued to receive either Futimeiwei or Budigefu treatment when discharged from hospital,and the therapeutic effects were evaluated at 1 month of treatment.The evaluation indicators included blood gas analysis,lung function,inflammatory factors and adverse drug reactions.RESULTS:After treatment,the arterial partial pressure of oxygen(PaO2)and oxyhemoglobin saturation(SaO2)of both groups were higher and the partial pressure of carbon dioxide(PaCO2)of both groups was lower than those before treatment,with statistically significant difference(P<0.05);while the differences in PaO2,PaCO2 and SaO2 between two groups after treatment were not statistically significant(P>0.05).After treatment,the the forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC)and FEV1/FVC of both groups were higher than those before treatment,the increasing trends of FEV1,FVC and FEV1/FVC of Budigefu group were higher than those of Futimeiwei group,with statistically significant differences(P<0.05).After treatment,the serum C reaction protein and interleukin 6 levels of both groups were lower than those before treatment,and those of Budigefu group was lower than the Futimeiwei group,with statistically significant differences(P<0.05).There were no statistically significant differences in incidences of adverse drug reactions including abnormal hepatic and renal function,pneumonia,headache,rash and gastroesophageal reflux between two groups(P>0.05).CONCLUSIONS:Bacterial lysate capsules combined with Futimeiwei and Budigefu in the treatment of AECOPD in elderly patients can effectively improve arterial blood gases,Budigefu has better effects in improving pulmonary function and anti-inflammatory,without increasing adverse drug reactions.
关键词
慢性阻塞性肺疾病/细菌溶解产物胶囊/氟替美维/布地格福Key words
Chronic obstructive pulmonary disease/Bacterial lysate capsules/Futimeiwei/Budigefu引用本文复制引用
基金项目
2021年安徽省重点研究与开发计划项目(202104j07020052)
出版年
2024
国家科技期刊平台
NSTL
万方数据